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The global burden of cancer is rising at an alarming rate. It remains as one of the top
causes of morbidity and mortality worldwide. It is predicted that within 2020, there will be
15 million new cases of cancer in the world, with cancer-related deaths increasing to 12
million. According to the World Health Organization (WHO), the global cancer burden is
expected to surge 57% worldwide in the next 20 years. A significant rise in cancer
burden will occur in the low-income and middle-income (developing) countries not only
due to demographic shifts, but also by the transition of risk factors due to globalization of
economies and behavioral patterns mirroring high-income economies (developed
countries). The rise in global cancer burden and the urgency to fight against cancer has
lead to cancer control being termed as a “global health priority. This alarming rise in
cancer burden will require a renewed attention for control, prevention and early detection
of cancer that can complement the improved treatments. The understanding of the
global trends and regional and socio-economic variations of cancer incidence and
mortality would help global health workforce design strategies for prevention, early
detection and develop unified global and region-specific plans to coordinate and improve
health care environment and patient health.
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Chapter I
INTRODUCTION
An overview of global cancer burden as a global health priority
According to the World Health Organization (WHO), the global cancer burden is
expected to surge 57% worldwide in the next 20 years. This alarming rise in cancer
burden will require a renewed attention for control, prevention and early detection of
cancer that can complement the improved treatments. The rise in global cancer burden
and the urgency to fight against cancer has lead to cancer control being termed as a
“global health priority”. 1-5
The total number of deaths associated with cancer reached 8 million in 2010,
which correlates to about 15% of all deaths worldwide.6 It has been estimated that 33%
to 50% of cancers can be prevented through control or avoidance of known risk factors.7
Additionally, a significant proportion of the remaining 50% of cancer related deaths could
be prevented through early detection and effective treatment strategies. Therefore as
noted by Drs. Ilbawi and Anderson2, it is critical to prioritize cancer interventions in the
global health agenda in which non-communicable diseases (NCDs) including cancer
receive less than 3% of the total donor development assistance for health ($503 Million
out of $22 Billion per year).2 Epidemiological data obtained from developed (higherincome) countries indicate that the prevention and early detection programs have been
somewhat successful at decreasing cancer deaths.8 However, the real challenge and
difficulty has been the translation of these prevention and early detection programs to
less developed (low-and middle-income) countries. Some of the major hurdles faced in
these countries include less effective health care system and lack of cancer awareness,
competing health priorities, use of carcinogens, low funding for health care reforms and
limited health care workforce with specialized training.9 In the less developed nations,

	
  

2

65% of the cancer-related deaths occur annually, however the global health resources
directed towards these countries constitute only about 5%.
Global heath priority of cancer control is designed towards three primary goals: i)
prevention of preventable cancer ii) cure of curable cancer and iii) palliate cancers for
which prevention and/or cure is not achieved.2 Cancer affects all regions and
communities worldwide. However, the prevalence and type of cancer shows marked
variation among communities. As discussed above, the total burden of cancer remains
highest in the affluent countries, but the low-and middle-income countries are narrowing
that gap at a very rapid pace. As the low-and middle-income countries succeed in
attaining the lifestyle of higher-income countries, they will face with increased cancer
burden.
It is important for global health workforce to understand the global burden of
cancer. Several factors lead to the “globalization” of cancer.10 The rapid aging of
population is increasing the cancer burden. Other critical factors include diet, tobacco
and use of harmful substances and infectious agents. The understanding of the global
trends and regional and socio-economic variations would help global health leadership
design strategies for prevention, early detection and develop unified global and regionspecific strategies to coordinate and improve health care environment and patient
health. The Human Development Index (HDI) is an important classifier for the
globalization of cancer.11 The HDI takes into account education, life expectancy and
national income to categories countries into one of four levels of human development:
low, medium, high and very high. It is well known that the communicable diseases and
nutrition related disorders are still the most common causes of death in low-HDI
countries. However, the projections are that NCDs, including cancer, will overtake the
communicable diseases and nutrition related diseases by 2030.12 The projected
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increase in global cancer burden—from 12·7 million new cases in 2008, to 22·2 million
by 2030 —indicates population growth and an evolving age distribution together with
other important changes in underlying incidence, allied to the prevalence and distribution
of risk factors.
The key points related to the global cancer burden is highlighted below:
•

In 2012, there were >14 million new cancer cases and >8 million cancer deaths. Figures
1, 2 and 3 shows the worldwide distribution of incidence, mortality and prevalence of
cancer. Table 1 lists the global cancer burden with the current incidence and mortality
rates for all cancers across the world. Table 2a,b shows the global burden of different
cancers for both sexes, all ages combined. Table 3 shows the global cancer burden
(incidence and mortality) for all cancers across the world and the more developed and
less developed regions of the world. It is observed that the more developed regions have
higher cancer burden compared to less developed regions.

•

For women, breast cancer was the leading cancer globally and in developed and
developing countries.

•

For men, lung cancer was the leading cancer globally and in developed and developing
countries.

•

For men, incident cases have increased the most for prostate cancer at the global
setting and in developed and developing countries.

•

For women at the global level, incident cases have increased the most for non-Hodgkin
lymphoma; in developed countries, incident cases have increased the most for kidney
cancer; in developing countries, incident cases have increased the most for breast
cancer.

•

More developed regions have higher incidence of cancer compared to less developed
regions.
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In the following chapters, we will discuss prediction or time trends in pancreatic
and liver cancer with respect to geographic locations; socio-economic status and
demographic shift using the well-defined predictions from GLOBOCAN 2012 across
geographical and socio-economical divide. Pancreatic cancer (PC) is a lethal
malignancy that accounts for about 4% of cancer-related deaths in both males and
females worldwide.13-24 In the United States, PC accounts for about 2.7% of all new
cancer cases and is projected to become the second largest cause of cancer-related
deaths by 2030.25 Liver cancer (LC) is fast developing into a global medical crisis26.
Historically, LC has been most prevalent in the developing regions of Southeast Asia
and Africa. This high burden of LC in these developing regions has been mainly
attributed to Hepatitis B virus (HBV) and exposure to aflotoxin27. However, in recent
years, developed Western countries have witnessed an alarming rise in LC partly due to
increased Hepatitis C virus (HCV) infection and non-communicable diseases (NCD)
associated with alcohol use and non-alcoholic steatohepatitis (NASH)26. LC is the fifth
most common cancer and the third leading cause of cancer-related deaths globally26,27.
Although the trends in the incidence and mortality of PC and LC are well studied in the
United States and some Western European countries, the same cannot be said for the
rest of the world. There are few publications on PC and LC originating from regions of
low incidence or resource-poor areas of the world.28 Similarly, there is a scarcity of
reports describing the overall global trends in the incidence and mortality of PC and LC
across all regions of the world and encompassing all strata of socio-economic
development.

Conclusion:
Prediction and time trends of the number of cases of incidence and mortality is quite
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relevant for health care planning purposes and allocation of available resources. The
demographic shift towards elder age groups worldwide and select geographic regions
over the next two decades is likely to contribute to an increase in cancer burden for
many cancer sites.
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Figure 1: Worldwide age-adjusted Incidence for all cancer excluding nonmelanoma skin cancer for both sexes
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Figure 2: Worldwide age-adjusted mortality for all cancer excluding nonmelanoma skin cancer for both sexes
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Figure 3: Worldwide age-adjusted prevalence for all cancer excluding nonmelanoma skin cancer for both sexes

	
  
Table 1 below shows the global cancer burden with the current incidence and
mortality rates for all cancers across the world.
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Table 2(a-b) below shows the global burden of different cancers for both sexes, all
ages combined.

Table 2a:

	
  
Table 2b:
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Table 3 below shows the global cancer incidence and mortality rates for all
cancers across the world and the more developed and less developed regions for
both male and female.
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Chapter II
METHODS
GLOBOCAN 2012
We utilized the GLOBOCAN 2012 database for obtaining data relating to the
incidence and mortality for PC for all regions of the world. GLOBOCAN 2012 is a
database that is maintained by the International Agency for Research on Cancer (IARC)
that compiles estimates of incidence and mortality for 27 major types of cancer. This
data includes information on all cancers that is stratified by gender for 184 countries and
30 world regions.29The detailed methodology used for the GLOBOCAN 2012 estimates
can be accessed via GLOBOCAN webpage30 and Ferlay et al (2015).29

World Health Organization (WHO) Regions
For the purposes of the study we utilized the geographic regions of the world
described by the WHO. The six WHO regions are: The WHO African Region (AFRO;
Region 1), WHO Region of the Americas (PAHO; Region 2), WHO Eastern
Mediterranean Region (EMRO; Region 3), WHO European Region (EURO; Region 4),
WHO South-East Asian Region (SEARO; Region 5), and WHO Western Pacific Region
(WPRO; Region 6). Detailed information can be found at WHO website with alphabetical
listing of the WHO Member States31

Human Development Index (HDI)
To account for the varying socio-economic standing of different countries/regions
of the world we adhered to the model of Human Development Index. The HDI been
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developed by the United Nations Development Programme (UNDP) provides a summary
measure of human development based on three fundamental areas of human
development: 1) life expectancy at birth, 2) adult literacy rate and primary education to
tertiary education enrolment rates, and 3) GDP per head adjusted for purchasing-power
parity [US$]).11 HDI uses complex statistical combinations to rank countries (187) into
four tiers of human development (from 0 to 1).11,32 The four tiers of human development
include: countries with very high HDI (HDI≥0.800; VHHD), countries with a high HDI
(HDI≥0.700; HHD), Medium HDI countries (HDI≥0.550; MHD), and countries with a low
HDI (HDI<0.550; LHD).

Age Standardized Rate (ASR)
The Age Standardized Rate (ASR) is the measurement of the rate of distribution
of population it would have if it had a standard age structure. The risk of developing
cancer is highly influenced by age and therefore standardization is necessary when
comparing several populations that differ with respect to age. The ASR data for all
analysis were obtained from GLOBOCAN 2012 database.29

Demographic Shift
Demographic shift (also referred as population ageing) is the shift in the
proportion of older population globally with the decline in fertility and increase in life
expectancy.33 This shift in population ageing is expected to have a profound effect on
cancer burden.29 The number of older persons (ages 60 and over) is the fastest growing
globally and is projected to be approximately 1.4 billion by 2030.33
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Statistical Analysis
R and SAS software (SAS Institute Inc., Cary, NC, USA) were used for statistical
analysis. Linear regression was used to evaluate trends in total incidence and mortality
for the world and by region from the prediction data obtained from GLOBOCAN 2012.
For these models, time was modeled as 1, 2, 3, 4, and 5 corresponding to years 2010,
2015, 2020, 2025, 2030, so the slope of the regression line can be interpreted as a 5
year increase in the outcome variable.
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Chapter III

Predictive global trends in the incidence and mortality of pancreatic cancer based
on geographic location, socio-economic status and demographic shift
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INTRODUCTION
In recent years, cancer control has been promoted as a global health priority.1-5 The
global cancer burden (GCB) is rising at an alarming rate and is expected to nearly
double by 2030.34-36 Pancreatic cancer (PC) is a lethal malignancy that accounts for
about 4% of cancer-related deaths in both males and females worldwide.13-24 In the
United States, PC accounts for about 2.7% of all new cancer cases and is projected to
become the second largest cause of cancer-related deaths by 2030.25
Although the trends in the incidence and mortality of PC are well studied in the
United States and some Western European countries, the same cannot be said for the
rest of the world. There are few publications on pancreatic cancer originating from
regions of low incidence or resource-poor areas of the world.28 Similarly, there is a
scarcity of reports describing the overall global trends in the incidence and mortality of
PC across all regions of the world and encompassing all strata of socio-economic
development.
The aim of this study is to describe the influence of geography (based on World
Health Organization [WHO] regional classification), socio-economic development (based
on Human Development Index [HDI]) and demographic shift on the global trends in the
incidence and mortality of PC. The intent of the study was not to develop an independent
model for predicting global cancer burden. It was aimed to review the predictive global
trends of pancreatic cancer based on the comprehensive data available in GLOBOCAN
2012 and present the results in a cogent fashion.

RESULTS
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Global PC Incidence and Mortality (for 2012) based on geography: worldwide and WHO
regions (Table 1)
The worldwide PC incidence including all ages and both sexes for 2012 is
estimated at 337,872 with an age-standardized rate (ASR) of 4.2 per 100,000. The
worldwide PC mortality including all ages and both sexes for 2012 is estimated at
330,391 with an ASR of 4.0 per 100,000. Among the different regions, the WHO region 6
(WPRO) is reported to have the highest incidence (113,015) whereas the highest
mortality is noted in WHO region 4 (EURO- 111,029).

Global PC Incidence and Mortality (for 2012) based socio-economic development (HDI)
(Table 1)
Comparison based on the four tier HDI model revealed striking differences in
incidence and mortality rate between VHHD, HHD, MHD and LHD (Table 1). Both men
and women from VHHD had much higher incidence and mortality (ASR) when compared
to HHD, MHD and LHD regions.

Global trends (2010-2030) in PC Incidence based on geography: worldwide and WHO
regions (Figure 1a)
Linear regression model was used to describe the trends in total PC incidence.
We noted a statistically significant increase in incidence of PC for the entire world
(p<0.001) with an average of 51,770 new cases every 5 years. Subset analysis for the
WHO regions again revealed a statistically significant increase in the incidence for all six
regions (p<0.001) with the most significant increases affecting region 6 (WPRO).
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Global trends (2010-2035) in PC Mortality based on geography: worldwide and WHO
regions (Figure 1 b)
We noted a statistically significant increase in PC mortality for the entire world
(p<0.001) with an average of 50,519 deaths every 5 years. Subset analysis for the WHO
regions also revealed a statistically significant increase in the PC-related mortality for all
six regions (p<0.001) with the most significant increases affecting region 6 (WPRO). The
prediction data used for the linear regression analysis were obtained from GLOBOCAN
for the global trends in incidence and mortality of PC (2010 – 2030) and are included in
Supplemental Table 1.

Effect of demographic change in PC incidence and mortality based on geography: for all
WHO Regions (Figures 2a and 2b)
Figure 2a shows the estimated combined number of new cases for Regions 1-6
(for all ages; ages <65 and ages ≥ 65) for PC between 2012 and 2030. It is observed
that the demographic shift in the total population will have a major influence on the
projected incidence of PC in 2030 due to an increase in the number of adults 65 years
and older. In addition to the rise in global PC incidence due to the demographic
changes, we also observed a similar substantial increase in PC mortality due to the
increase in the number of adults 65 years and older (Figures 2b).

Effect of demographic change in PC incidence and mortality based on socio-economic
development (HDI) (Figures 3 and 4)
We determined the future burden of PC in 2030 by gender and demographics for
the four levels of HDI on the basis of the rates in 2012. The Figures 3 and 4 and
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Supplemental Table 2 provide trends of PC among VHHD, HDH, MDH and LHD.
Overall, the highest incidence and mortality rates were observed for VHHD, followed by
HDH, MDH and LDH.
The influence of demographic shift on PC incidence and mortality revealed
striking findings for different HDI regions. The demographic shift contributed to a greater
rise in PC incidence and mortality for ages > 65 years in the regions of VHHD, HHD and
MHD. In contrast, although we noted a rise in the incidence and mortality in the region of
LHD for all ages, the increase predominantly affected the younger age group (< 65 years
of age).

DISCUSSION
The results of our study demonstrate that the global burden of PC is predicted to
rise significantly over the next 15 years. This rise in the global burden of PC is noted in
all geographic regions of the world. Similarly, the increase affects all regions of the world
regardless of the socio-economic development as noted by the rise in the burden in all 4
HDI regions. This is alarming considering the progress in reducing the burden of many
other cancers in some countries in the VHHD region.37 Kohler et al analyzed the data for
the major cancers in the US (1992-2011) and noted a significant decrease in the
incidence of prostate cancer (-2.5 to -10.5%), breast cancer (-0.4% to -2.2%) lung
cancer (-1.9 to 4.8% for men and -1.1 to 2.5 % for women) and colorectal cancer (-2.6 to
4.2% for men and -1.8% to -4.5%). Similarly, they noted a significant decrease in the
mortality for several cancers such as lung (-1.1 to -2.9% for men and -0.8 to -1.9% for
women), prostate (-0.5 to -4.1%), breast (-1.8 to -3.3%) and colorectum (-0.3 to -3.9%
for men and -1 to -2.9% for women). The rise in the global burden of PC despite
progress for other cancers in some parts of the world is a cause for concern.
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We noted several points of interest in the rising global burden of PC. In 2012,
region 6 (WPRO) and region 4 (EURO) accounted for the highest incidence and
mortality. Over the next 15 years, although the incidence and mortality increases in all
six regions, the rate of increase is not uniform. Whereas the PC related mortality is
highest in region 4 (EURO) in 2012, this will be surpassed by region 6 (WPRO) over the
next 15 years. The WPRO region with its 37 countries is home to nearly 1.8 billion
people and consists of some of the world’s least developed countries in addition to some
of the most rapidly emerging economies. Advance knowledge of these figures can help
public policy and debate to allocate resources to tackle this lethal malignancy in the least
developed countries.
There was a significant association noted between PC and socio-economic
status with the highest burden of PC seen in the VHHD countries. The ASR of PC
incidence and mortality in VHHD countries is nearly six to seven fold higher than for the
countries in the LHD strata. It is well known that there is a higher prevalence of the risk
factors associated with PC (dietary and lifestyle choices) seen in the VHHD countries. It
is likely that as more countries in the MHD and LHD regions transition to emerging
economies with improving socio-economic conditions we may see a migration of these
risk factors to those regions as well. Smoking, one of the most important risk factors for
pancreatic cancer is on the rise in the developing countries which account for nearly
70% of the global consumption.38 Obesity is another well-known risk factor for pancreatic
cancer.39,40 Countries in the economic transition phase are also known to go through a
nutrition transition phase with a rise in the rates of obesity. Popkin et al noted that
reduced physical activity and dietary changes in the 1990’s have led to an increase in
obesity rates in the developing countries.41
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Kolkman et al performed a comparative study of the histo-pathologic type of
esophageal cancer between a developed country (United States) and an emerging
economy (India).42 Although squamous cell carcinoma is the predominant type of cancer
in India, they noted a gradual increase in the rate of adenocarcinoma to correlate with
increase in risk factors specific for esophageal adenocarcinoma such as obesity. There
are several countries in the world that are in the zone of economic improvement, which
could be affected by rising burden of PC. Knowledge of the risk factors can help steer
public health measures that focus on increasing awareness and prevention.
The correlation between age and PC burden showed mixed results. Advancing
age (≥ 65) accounted for significant increases in PC incidence and mortality in VHHD,
HHD and MHD countries. In contrast, the majority of the new cases and mortality related
to PC in the LHD countries afflicts patients < 65 years of age and will continue to do so
in the future. This age group in the LHD countries tends to be the main income earners
and the rising PC burden in this segment can have significant adverse micro-economic
and macro-economic consequences.
In summary, the results of our study demonstrate that the global burden of PC is
expected to rise significantly over the next 15 years. Although some regions may
experience a disproportionate increase, the rise was noted in all regions of the world
regardless of the location socio-economic status, age and gender. We noted a definite
association between pancreatic cancer and higher socio-economic status, which may
contribute, to a rise in the future burden in countries with emerging economies. The
predilection for pancreatic cancer to affect younger populations in LHD countries can
have

significant

micro

and

macro-economic

adverse

consequences.

Advance

knowledge of this data can help formulate strategies to specifically target countries and
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populations and to also improvise public health policy to tackle this lethal disease on the
global stage.
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Figure 1: Trends in PC incidence (a) and mortality (b) based on worldwide and
WHO regions 1-6. Time was modeled here as 1, 2, 3, 4, 5 corresponding to years
2010, 2015, 2020, 2025, 2030, so the slope of the regression line can be interpreted
as a 5 year increase in the outcome variable.
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Figure 2. Effect of demographic change in PC incidence (a) and mortality (b) for
combined WHO Regions 1-6.

	
  

26

Figure 3. Effect of demographic change in PC incidence and mortality for VHHD
(a-b) and HHD (c-d).

	
  

27

Figure 4. Effect of demographic change in PC incidence and mortality for MHD (ab) and LHD (c-d).
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Table 1. PC incidence and mortality statistics for 2012 based on worldwide, WHO
regions 1-6 and HDI.
Global pancreatic cancer burden based on geography: Worldwide and for the 6 WHO regions
(2012)
INCIDENCE
Estimate
d
incidenc
e, all
ages

Popula
tion (all
ages;
both
sex)

World

337872

Region 1

Population (all
ages; male)

Populati
on (all
ages;
female)

ASR (W)
(all ages;
both sex)

ASR (W)
(all ages;
male)

ASR (W) (all
ages; female)

178161

159711

4.2

4.9

3.6

8324

4304

4020

1.8

2.0

1.6

Region 2

75094

37016

38078

5.9

6.5

5.3

Region 3

7686

4503

3183

1.9

2.2

1.5

Region 4

110499

55795

54704

6.5

8.0

5.3

Region 5

23210

12401

10809

1.5

1.7

1.3

Region 6

113015

64116

48899

4.4

5.3

3.5

MORTALITY
Estimate
d
mortality
, all ages

Popula
tion
(both
sex)

Population
(male)

Populati
on
(female)

ASR (W)
(both sex)

ASR (W)
(male)

ASR (W)
(female)

World

330391

173827

156564

4.0

4.7

3.4

Region 1

8048

4174

3874

1.7

2.0

1.5

Region 2

73751

36477

37274

5.6

6.4

5.0

Region 3

7440

4353

3087

1.8

2.1

1.5

Region 4

111029

56350

54679

6.4

7.9

5.1

Region 5

21638

11522

10116

1.4

1.5

1.2

Region 6

108444

60926

47518

4.1

5.0

3.3
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Global pancreatic cancer burden based on socio-economic development: For the 4 HDI
regions (2012)
INCIDENCE
Estimated
incidence, all
ages

Populati
on (all
ages;
both sex)

Populati
on (all
ages;
male)

Populati
on (all
ages;
female)

ASR (W)
(all ages;
both sex)

ASR (W)
(all ages;
male)

ASR (W) (all
ages; female)

Very High
Human
Development

174344

87924

86420

7.2

8.5

6.1

High Human
Development

55638

28491

27147

4.6

5.4

3.9

Medium
Human
Development

98632

56902

41730

2.7

3.3

2.2

Low Human
Development

9108

4767

4341

1.2

1.4

1.1

MORTALITY
Estimated
incidence, all
ages

Populati
on (all
ages;
both sex)

Populati
on (all
ages;
male)

Populati
on (all
ages;
female)

ASR (W)
(all ages;
both sex)

ASR (W)
(all ages;
male)

ASR (W) (all
ages; female)

Very High
Human
Development

170497

85643

84854

6.8

8.0

5.6

High Human
Development

56474

29254

27220

4.6

5.6

3.8

Medium
Human
Development

94447

54242

40205

2.6

3.2

2.1

Low Human
Development

8822

4610

4212

1.2

1.3

1.1

	
  
PC= Pancreatic cancer
ASR= Age standardized rate
Region 1= AFRO (Africa)
Region 2= PAHO (Americas)
Region 3= EMRO (Eastern Mediterranean)
Region 4= EURO (Europe)
Region 5= SEARO (South East Asia)
Region 6= WPRO (Western Pacific)
HDI= Human Development Index
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Chapter IV

Global trends in liver cancer epidemiology based on geographic location, socioeconomic status and demographic shift.
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INTRODUCTION
Liver cancer (LC) is fast developing into a global medical crisis26. Historically, LC has
been most prevalent in the developing regions of Southeast Asia and Africa. This high
burden of LC in these developing regions has been mainly attributed to Hepatitis B virus
(HBV) and exposure to aflotoxin27. However, in recent years, developed Western
countries have witnessed an alarming rise in LC partly due to increased Hepatitis C virus
(HCV) infection and non-communicable diseases (NCD) associated with alcohol use and
non-alcoholic steatohepatitis (NASH)26. LC is the fifth most common cancer and the third
leading cause of cancer-related deaths globally26,27.
The trends in the incidence and mortality of LC have been well studied for certain
developing regions of high incidence and few developed regions. However, there is
scarcity of comprehensive reports unpinning the incidence and mortality trend for LC
across all geographic regions and encompassing all strata of socio-economic
development.
The aim of this epidemiological study is to critically dissect the influence of geography
(based on World Health Organization [WHO] regional classification), socio-economic
development (based on Human Development Index [HDI]) and demographic shift on the
global trends in the incidence and mortality of LC.

RESULTS
Global LC Incidence and Mortality (for 2012) based on geography: worldwide and WHO
regions (Figure 1a,b)
The worldwide LC incidence and mortality has been shown in Figure 1a. The
global LC incidence including all ages and both sexes for 2012 is estimated at 782,451
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with an age-standardized rate (ASR) of 10.1 per 100,000. The worldwide LC mortality
including all ages and both sexes for 2012 is estimated at 745,533 with an ASR of 9.5
per 100,000. Among the different regions, the WHO region 6 (WPRO) is reported to
have both the highest incidence (500,506) and mortality (476,692) accounting for about
64% of all LC incidence and mortality (Figure 1b).

Global LC Incidence and Mortality (for 2012) based socio-economic development (HDI)
(Figure 1b)
Comparison based on the four tier HDI model revealed striking differences in
incidence and mortality rate between VHHD, HHD, MHD and LHD (Figure 1b). The
incidence and mortality of LC does not follow any particular socio-economic pattern. The
MHD area has the highest incidence (531,931) and mortality (514,528) rates for all ages
and both sexes combined. The VHHD areas are next with high incidence (153,946) and
mortality (133,159) rates. The HHD and LHD areas have comparable incidence and
mortality rates.
Supplemental Table 1 shows the estimated LC incidence and mortality (2012) for
worldwide and WHO regions and HDI areas for all ages for both male and female.
Overall, the LC incidence and mortality is higher in male than female.

Global LC 5-years prevalence (for 2012) based on geography: worldwide and WHO
regions (Supplemental Figure 1a,b)
The worldwide LC 5-years prevalence (proportions per 100,000) for male and
female population has been shown in Supplemental Figure 1a. The global LC 5-years
prevalence for male is estimated at 453,345 (proportion = 17.5%). The global LC 5-years
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prevalence for female is estimated at 179,825 (proportion = 6.9%). Among the different
regions, the WHO region 6 (WPRO) is reported to have both the highest 5-years
prevalence for male (proportion = 41.9%) and female (proportion = 15.4%; Supplemental
Figure 1b).

Global LC 5-years prevalence (for 2012) based socio-economic development (HDI)
(Supplemental Figure 1b)
Comparison based on the four tier HDI model revealed an intriguing difference in
the 5-years prevalence between VHHD, HHD, MHD and LHD (Supplemental Figure 1b).
In contrast to the highest incidence and mortality rates discussed above for MHD area,
the VHHD area has the highest 5-year prevalence for both male (proportion = 28.4%)
and female (proportion = 11.7%). MHD area is second ranked with 5-year prevalence for
both male (proportion = 20.7%) and female (proportion = 7.4%). The HHD and LHD
areas have comparable 5-years prevalence rates.

Socio-economic variability within WPRO regional countries (Table 1, Supplemental
Table 2a,b and Table 2)
Table 1 lists the estimated LC incidence and mortality (2012) for all WPRO
regional countries (for all ages; both sexes). It is observed that China contributed to
about 84.5% and 86.3% of all WPRO incidence and mortality respectively. However, the
ASR (worldwide) is higher than China (22.3) for several other WPRO countries including
Mongolia (78.1), Lao PDR (52.6), Viet Nam (24.6) and Republic of Korea (22.8).
Supplemental Table 2a shows the WPRO liver cancer estimates of incidence and
mortality by different age groups. Interesting, the both male and female ages >= 75, the
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rate of mortality is higher compared to the incidence. Supplemental Table 2b shows the
top 6 WPRO member states LC estimates by age. An alarming observation is the
relatively early onset of LC incidence and mortality for Mongolia and Lao PDR.
Table 2 is the categorization of the different WPRO member states based on
their HDI 2014 ranking, life expectancy, physician availability and health expenditure of
the country. It is important to note that China as per Human Development Report 2014 is
listed within the HHD category. China’s HDI increased over the past three decades from
0.423 (1980) to 0.719 (2013). The GLOBOCAN 2012 estimates for incidence, mortality
and trend predictions are based on data obtained prior to 2012 and have listed China
within the MHD category. Within the WPRO countries, Australia and New Zealand are
within the top 5 VHDD areas and has low incidence and mortality of LC [ASR(W) of 4.2
and 4.0 respectively]. While the health expenditure (as % of GDP) in Australia and New
Zealand is an impressive 9.0 and 10.1 respectively, areas with high LC incidence and
mortality like China (5.2%), Mongolia (5.3%), Republic of Korea (7.2%), Cambodia
(5.7%) have moderate level of health expenditure. Lao PDR, a low human development
area has the lowest health expenditure at 2.8% and shows high ASR(W) and early onset
of LC incidence and mortality. It is also important to note that the life expectancy at birth
is significantly different within these WPRO countries based on socio-economic status.

Global trends (2010-2030) in LC Incidence based on geography: worldwide and WHO
regions (Figure 2a)
Linear regression model was used to determine the trends in total LC incidence.
We noted a statistically significant increase in incidence of LC for the entire world
(p<0.0001) with an average of 117,075 new cases every 5 years. Subset analysis for the
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WHO regions again revealed a statistically significant increase in the incidence for all six
regions with the most significant increases affecting region 6 (WPRO; p<0.0001).

Global trends (2010-2030) in LC Mortality based on geography: worldwide and WHO
regions (Figure 2b)
We noted a statistically significant increase in LC mortality for the entire world
(p<0.0001) with an average of 112,160 deaths every 5 years. Subset analysis for the
WHO regions also revealed a statistically significant increase in the LC-related mortality
for all six regions (p<0.001) with the most significant increases affecting region 6
(WPRO; p<0.0001).

Effect of demographic change in LC incidence and mortality in WPRO Region (Figures
3a,b)
Figure 3a shows the estimated number of new cases for WPRO Region (for all
ages; ages < 65 and ages ≥ 65 years) for LC between 2012 and 2030. It is observed that
the demographic shift in the total population will have a major influence on the projected
incidence of LC in 2030 due to an increase in the number of adults 65 years and older.
In addition to the rise in LC incidence due to the demographic changes, we also
observed a similar substantial increase in LC mortality in WPRO Region due to the
increase in the number of adults 65 years and older (Figures 3b). It is important to note
that the number of LC incidence for 2012 was higher in the younger population ages <
65 years by more than 30,000. However, the predicted LC incidence is expected to shift
towards the older population ages 65 years and older with an approximate increase of
about 35,000 patients by 2030.

	
  

37

Effect of demographic change in LC incidence and mortality based on socio-economic
development (HDI) (Supplemental Figures 2-5)
We determined the future burden of LC in 2030 by gender and demographics for
the four levels of HDI on the basis of the rates in 2012. The Supplemental figures 2 to 5
provide trends of LC among VHHD, HHD, MHD and LHD. Overall, the highest incidence
and mortality rates were observed for MHD, followed by VHDH, LDH and HDH. Thus,
the demographic shift does not follow any particular socio-economic pattern.
The influence of demographic shift on LC incidence and mortality revealed
striking findings for different HDI regions. The demographic shift predicts a greater rise in
LC incidence (227,282) and mortality (236,431) for adults older than ages 65 years in
the regions of MHD area compared to 111,212 and 102,316 for incidence and mortality
respectively for ages < 65 years. In contrast, although we noted a rise in the incidence
(36,984) and mortality (35,122) in the region of LHD for all ages, the increase
predominantly affected the younger age group (< 65 years of age).

DISCUSSION
The global burden of cancer is rising at a precarious rate and has been the leading
cause of death worldwide1-5,34-36. Intriguingly, LC has catapulted itself as one of the
deadliest forms being the second most-common case of cancer-related death
worldwide26,27,29. As per the American Cancer Society, the 5-year relative survival rate
after diagnosis is approximately 28% for localized, 7% for regional and 2% for distant
metastasis43. The combined 5-year relative survival rate from LC is about 15% in US and
about 12% in Europe43,44. One of the challenges for LC patients and clinicians is that LC
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is not manifested during early stages and is often diagnosed at an advanced stage,
thereby causing a poor 5-year relative survival rate.
The results of our study demonstrate that the global burden of LC is predicted to
rise significantly over the next 15 years. This rise in the global burden of LC is noted in
all geographic regions of the world. However, the highest rate of LC incidence and
mortality is observed in WPRO region accounting for about 64% of all LC incidence and
mortality. The LC burden was second highest in SEARO, followed by EURO, PAHO and
AFRO regions. Similarly, the increase affects all regions of the world regardless of the
socio-economic development as noted by the rise in the burden in all 4 HDI regions. The
highest LC burden was observed in the MHD areas. However, an interesting finding in
this study is that 5-years prevalence of LC is highest in VHHD area (28.4% and 11.7%
for male and female) compared to MHD (20.7% for male and 7.4% for female).
Therefore, the incidence of LC is increasing at a higher proportion for the more
developed/VHHD countries. Considering the progress VHHD countries have made
towards reducing the cancer burden for several types of cancer37, the increase in the 5years prevalence of LC for both men and women are alarming and needs detailed
analysis. In the annual report on cancer burden for major cancer types in the US (19922011), Kohler et al noted a significant decrease in the incidence of prostate cancer (-2.5
to -10.5%), colorectal cancer (-2.6 to 4.2% for men and -1.8% to -4.5%), lung cancer (1.9 to 4.8% for men and -1.1 to 2.5 % for women) and breast cancer (-0.4% to -2.2%).
Similarly, they observed a significant decrease in the mortality for certain cancer types
including breast (-1.8 to -3.3%), colorectum (-0.3 to -3.9% for men and -1 to -2.9% for
women), lung (-1.1 to -2.9% for men and -0.8 to -1.9% for women) and prostate (-0.5 to 4.1%). Therefore, the rise in the LC burden despite progress for other cancers in some
parts of the world is a cause for concern.
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We noted several points of interest in the rising global burden of LC in WPRO
region. The WPRO region is consisting of 37 countries with a combined population of
nearly 1.8 billion people. It consists of an mélange of world’s least developed countries
in addition to some of the most rapidly emerging economies. As noted in Table 2, the
HDI rankings of the member countries within WPRO regions span across all 4 HDI areas
and spreads across Australia (VVHD rank 2nd) to Solomon Islands and Papua New
Guinea (LHD rank 157th). Therefore, advanced knowledge of these figures can help
public policy and debate to allocate resources to tackle this lethal malignancy in the least
developed countries.
We did not observe a significant association between LC and socio-economic
status with the highest burden of LC seen in the MHD countries. The ASR of LC
incidence and mortality in MHD countries is > 2 fold greater than for the countries in the
VHHD and LHD strata and >3 fold greater than HHD countries. It is well known that
there is a higher prevalence of the risk factors associated with LC (dietary and lifestyle
choices) seen in the MHD, HHD and VHHD countries. It is likely that as more countries
in the LHD regions transition to emerging economies with improving socio-economic
conditions we may see a migration of some of these risk factors to those regions as well.
Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) are the strongest
risk factors for hepatocellular carcinoma (HCC), the histological type that is responsible
for majority of LC worldwide. HCC can develop after many years of infection with either
of these viruses. HBV and HCV are both highly contagious diseases that can be passed
from person to person through blood (such as by sharing needles) or sexual contact.
There is strong evidence of the association of obesity (high BMI), long term consumption
of alcoholic drinks (three or more per day) and heavy exposure to aflatoxins (toxins
secreted by certain fungi) with the development of LC. Aflatoxins are produced mainly
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due to improper storage of food in warmer climatic regions of the world. Major foods that
are contaminated by aflatoxins include various types of nuts including peanuts,
pistachios, and Brazil nuts. Other common contaminating food includes grains, chilies,
black pepper and dry fruits. Aflatoxin exposure accentuates the development of HCC
from HBV infection and has been partly contained with better storage of grains. Dietary
and lifestyle modifications in several developing countries has been able to reduce
obesity and diabetes, which are associated with HCV-infected population. As per the
emerging 2015 reports from the World Cancer Research Fund International –
Continuous Update Project (CUP), limited reports have shown that higher consumption
of fish and regular physical activity decreases the risk of LC.
The correlation between age and LC burden showed mixed results. Advancing
age (≥ 65) accounted for significant increases in LC incidence and mortality in MHD,
HHD and VHHD countries. In contrast, the majority of the new cases and mortality
related to LC in the LHD countries afflicts patients < 65 years of age and will continue to
do so in the future. This age group in the LHD countries tends to be the main income
earners and the rising LC burden in this segment can have significant adverse microeconomic and macro-economic consequences.
In summary, the results of our study demonstrate that the global burden of LC is
expected to rise significantly over the next 15 years. Although the WPRO region may
experience a disproportionate increase, the rise was noted in all regions of the world
regardless of the location, socio-economic status, age and gender. We did not observe a
definite association between LC and higher socio-economic status, which may be
associated with variable risk factors. The predilection for LC to affect younger
populations in LHD countries can have significant micro and macro-economic adverse
consequences. Advance knowledge of this data can help formulate strategies to
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specifically target countries and populations and to also improvise public health policy to
tackle this lethal disease on the global stage.
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Figure 1: LC incidence and mortality worldwide by WHO and HDI classification (for
all ages and both sexes)

	
  

43

Figure 2a,b: Time Trend in liver cancer incidence and mortality for WHO regions
2010 – 2030. Time was modeled here as 1, 2, 3, 4, 5 corresponding to years 2010,
2015, 2020, 2025, 2030, so the slope of the regression line can be interpreted as a
5 year increase in the outcome variable.
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Figure 3a,b: Effect of demographic shift on the incidence (a) and mortality (b)
rates in WPRO regions (2012 – 2030)

	
  
Table 1: LC incidence and mortality in WPRO region 6 (for both sexes; all ages)

45
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Table 2: Categorization of WPRO regional members based on HDI rank, life
expectancy, physicians and health expenditure.
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Supplemental Figure 1a,b: LC estimated incidence and 5-year prevalence
(proportion) worldwide by WHO and HDI classification for male (a) and female (b)
of all ages
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Supplemental Figure 2a,b: Effect of demographic shift on the incidence (a) and
mortality (b) rates in MDH areas (2012 – 2030)
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Supplemental Figure 3: Effect of demographic shift on the incidence and mortality
rates in LDH areas (2012 – 2030)
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Supplemental Figure 4a,b: Effect of demographic shift on the incidence (a) and
mortality (b) rates in VHHD areas (2012 – 2030)
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Supplemental Figure 5a,b: Effect of demographic shift on the incidence (a) and
mortality (b) rates in HHD areas (2012 – 2030)
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Supplemental Table 1: LC incidence and mortality worldwide by WHO and HDI
classification (for male and female; all ages)

	
  

53

Supplemental Table 2a,b: LC incidence and mortality in WPRO region 6 by age (for
male and female) (a). LC incidence and mortality in TOP 6 WPRO member states
by age (for both sexes) (b)
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Chapter V
Summary
The time trends in cancer incidence and mortality vary substantially for different
countries. The cancer transition in low-and medium-HDI countries combined with
growing and ageing population means that many countries are facing a double burden of
cancer – that is the burden associated with infectious agents combined with an
increasingly westernized lifestyle. The global cancer burden is expected to increase in all
countries due to population growth, aging, and an increasing prevalence of certain risk
factors. This outstanding global health concern has been well responded by the health
community through the endorsement of the “25 by 25” strategy as part of the NCD
Global Monitoring Framework. The goal of the NCD Global Health Framework is to
reduce avoidable mortality from NCDs by 25% by 2025 through the support and active
participation from all levels of society.45 The “25 by 25” strategy would be expected to
represent a decrease of 25% premature cancer deaths each year by 2025 (a reduction
of 1.5 Million from a predicted 6 Million premature cancer deaths in people aged 30-69
years). The achievement of the 25% reduction in premature cancer deaths will need
more effective prevention, to reduce incidence, and more effective health systems, to
improve survival. As aptly put forth by Drs. Paolo Vineis and Christopher P Wild, “Cancer
is a global and growing, but not uniform, problem.”7 The primary prevention of cancer is
the effective and cost-effective way to fight the war against cancer with 33% to 50% of
cancers that are preventable. The progress of cancer control strongly depends on the
complementation of cancer prevention with early detection and effective treatments.
Unfortunately, the current socio-economic trends globally do not promote prevention
since it takes time to manifest and lacks strong leadership/policy advocates.

	
  

55

Final thoughts
A topic of continuous global health debate is the usefulness to identify differences in
cancer incidence and mortality trends between countries, between regions within a
country, or between populations defined by racial or ethnic group or socio-economic
status. The concern put forth is that whether the differences noted above have any effect
on the health policy or the public especially because the countries being compared have
widely different economic development, some of them extremely poor, others with civil
conflicts. Anderson and colleagues1 have put forth hypothesis that the information on the
global trends and disparities in cancer burden can help focus debate on reducing
geographical, racial and/or ethnic disparities. Groundbreaking research by Bray and
colleagues46 have demonstrated that long term surveillance of worldwide trends in
cancer incidence has provided data for causal research and the basis for prevention and
screening. It is expected that the continuous global surveillance of cancer would provide
an impetus for alteration in healthcare policy and healthcare systems and serve as a key
metric for the global cancer control.
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